Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48 hours - 01/06/24
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Graphical abstract |
Highlights |
• | About 10% of patients with ACS are treated by VKAs or NOACs. | ||||
• | The initial management of these patients is highly complex. | ||||
• | New guidelines specify that, only during PCI, a bolus of UFH is recommended if:
| ||||
• | No randomized study has been performed in this specific population. | ||||
• | Proposed algorithms are therefore a synthesis of diagnostic/therapeutic approaches. |
Abstract |
Around 10% of patients with acute coronary syndrome are treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants for various indications. The initial management of these patients is highly complex, and new guidelines specify that, only during percutaneous coronary intervention, a bolus of unfractionated heparin is recommended in one of the following circumstances: (1) if the patient is receiving a non-vitamin K antagonist oral anticoagulant; or (2) if the international normalized ratio is<2.5 in a patient being treated with a vitamin K antagonist. In this review, we report on five key messages essential for the management of these patients. There are no randomized studies to date, and we propose two diagnostic and/or therapeutic decision algorithms. However, randomized studies are needed to validate these strategies.
El texto completo de este artículo está disponible en PDF.Keywords : Acute coronary syndrome, Vitamin K antagonist, Non-vitamin K antagonist oral anticoagulant, Atrial fibrillation, Bleeding
Esquema
| ☆ | Tweet: About 10% of patients with acute coronary syndrome receive anticoagulants. Initial management is highly complex, and new guidelines recommend unfractionated heparin only under specific circumstances. In this review, we report on five key messages for managing these patients. |
Vol 117 - N° 5
P. 351-357 - mai 2024 Regresar al número
Artículo precedente
- Management and outcomes of pregnant women with cardiovascular diseases in a cardio-obstetric team
- Marjorie Richardson, Jean Philippe Bonnet, Capucine Coulon, Olivia Domanski, Benjamin Constans, Max Gonzalez Estevez, Sophie Gautier, Luisa Marsili, Yasmine Ould Hamoud, Augustin Coisne, Hélène Ridon, Anne-Sophie Polge, Stéphanie Mouton, Yasmine Haddad, Francis Juthier, Mouhamed Moussa, Claire Mounier Vehier, Gilles Lemesle, Guillaume Schurtz, Charles Garabedian, Mercedes Jourdain, Sandro Ninni, François Brigadeau, David Montaigne, Nicolas Lamblin, Louise Ghesquiere
- Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology
- François Diévart, Eric Bruckert, Victor Aboyans, Saïd Bekka, Franck Boccara, Barthelemy Bourdon Baron Munoz, Joseph Emmerich, Michel Farnier, Antonio Gallo, Gilles Lemesle, François Paillard, François Schiele, Serge Kownator, Heart, Vessels and Metabolism Group of the French Society of Cardiology
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.